Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph T Hull

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Psychopharmacology Bulletin|June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHDAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
CNS Drugs|July 27, 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Joseph T Hull, Soumya A Chaturvedi, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Cognitive Neuroscience|July 18, 2013
Blue light stimulates cognitive brain activity in visually blind individualsGilles Vandewalle, Olivier Collignon, Joseph T Hull, et al.
Plos One|April 19, 2012
Analysis method and experimental conditions affect computed circadian phase from melatonin dataHadassa Klerman, Melissa A St Hilaire, Richard E Kronauer, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Scientific Reports|November 18, 2018
Light modulates oscillatory alpha activity in the occipital cortex of totally visually blind individuals with intact non-image-forming photoreceptionGilles Vandewalle, Markus J van Ackeren, Véronique Daneault, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 12, 2012
Melanopsin and rod-cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humansJoshua J Gooley, Ivan Ho Mien, Melissa A St Hilaire, et al.
Current Biology : CB|December 18, 2007
Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retinaFarhan H Zaidi, Joseph T Hull, Stuart N Peirson, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Psychopharmacology Bulletin|June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHDAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
CNS Drugs|July 27, 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Joseph T Hull, Soumya A Chaturvedi, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Cognitive Neuroscience|July 18, 2013
Blue light stimulates cognitive brain activity in visually blind individualsGilles Vandewalle, Olivier Collignon, Joseph T Hull, et al.
Plos One|April 19, 2012
Analysis method and experimental conditions affect computed circadian phase from melatonin dataHadassa Klerman, Melissa A St Hilaire, Richard E Kronauer, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Scientific Reports|November 18, 2018
Light modulates oscillatory alpha activity in the occipital cortex of totally visually blind individuals with intact non-image-forming photoreceptionGilles Vandewalle, Markus J van Ackeren, Véronique Daneault, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 12, 2012
Melanopsin and rod-cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humansJoshua J Gooley, Ivan Ho Mien, Melissa A St Hilaire, et al.
Current Biology : CB|December 18, 2007
Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retinaFarhan H Zaidi, Joseph T Hull, Stuart N Peirson, et al.
Pageof 3